- Biohaven (BHVN, Financial) encounters a setback as it withdraws its EU marketing application for Dazluma.
- Analysts predict significant upside potential with a one-year average target price of $60.46.
- The stock holds an "Outperform" consensus recommendation from top brokerage firms.
Biohaven Ltd (BHVN) has faced a challenging period as its shares took a hit after announcing the withdrawal of its EU marketing application for Dazluma, a promising treatment aimed at spinocerebellar ataxia. While this may seem a setback, the company is proactively gathering more comprehensive data to reinforce its position for a future resubmission. Investors can look forward to a decision from the U.S. FDA regarding Dazluma, expected in the third quarter of 2025.
Wall Street Analysts' Forecasts for Biohaven
According to the projections from 13 market analysts, the outlook for Biohaven Ltd (BHVN, Financial) remains optimistic with a one-year average target price set at $60.46. This forecast reveals an impressive potential upside of 193.79% from its current trading price of $20.58. Analysts' estimates range from a low of $39.00 to a high of $76.00, reflecting varied expectations about the company’s recovery and growth prospects. For a deeper dive into these financial forecasts, be sure to visit the Biohaven Ltd (BHVN) Forecast page.
The broader investor sentiment remains positive, supported by the consensus recommendation from 16 brokerage firms. Biohaven Ltd (BHVN, Financial) currently holds an average brokerage recommendation of 1.6, labeling it as "Outperform." On this rating system, a score of 1 indicates a "Strong Buy," while 5 suggests a "Sell," placing Biohaven in a favorable position for potential investors.
